Charles K. Gayer - 19 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
President and CCO
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
19 Dec 2025
Net transactions value
+$286,851
Form type
4
Filing time
23 Dec 2025, 16:08:40 UTC
Previous filing
19 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gayer Charles K President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM /s/ Alane P. Barnes, by power of attorney 23 Dec 2025 0001800110

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Tax liability $85,045 -11,477 -1.3% $7.41 878,350 19 Dec 2025 Direct F1
transaction BCRX Common Stock Options Exercise $45,537 +14,142 +1.6% $3.22 892,492 22 Dec 2025 Direct
transaction BCRX Common Stock Options Exercise $50,859 +10,091 +1.1% $5.04 902,583 22 Dec 2025 Direct
transaction BCRX Common Stock Options Exercise $275,500 +50,000 +5.5% $5.51 952,583 22 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -14,142 -100% $0.000000 0 22 Dec 2025 Common Stock 14,142 $3.22 Direct F2
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -10,091 -37% $0.000000 17,409 22 Dec 2025 Common Stock 10,091 $5.04 Direct F2
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -50,000 -100% $0.000000 0 22 Dec 2025 Common Stock 50,000 $5.51 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units. This transaction does not represent a sale by the reporting person.
F2 The option grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.